Stemline Therapeutics Inc.

• A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer Recruiting
  2025-524168-39-00 Phase I 1 country
• A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting
  2024-512926-27-00 Phase III 7 countries ELACESTRANT; EVEROLIMUS
• A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer Recruiting
  2024-514661-19-01 Phase I 1 country
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting
  2024-515445-42-00 Phase III 15 countries
• A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B… Recruiting
  2022-503114-23-00 Phase I (Other) 8 countries
• This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a Phase 2 evaluation of elacestran… Recruiting
  2024-512878-98-00 Phase I/II 6 countries ELACESTRANT
• ELACESTRANT in Women and Men with CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label … Ended
  2023-503214-68-00 Phase II 2 countries ELACESTRANT

Showing 1–7 of 7 trials